Gershenson D M, Silva E G, Mitchell M F, Atkinson E N, Wharton J T
Department of Gynecology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Am J Obstet Gynecol. 1993 Apr;168(4):1178-85; discussion 1185-7. doi: 10.1016/0002-9378(93)90365-p.
The purpose of this study was to compare patients with advanced-stage transitional cell carcinoma of the ovary with those who had poorly differentiated serous carcinoma for surgical response and survival.
Sixty-two patients with transitional cell carcinoma were identified through a retrospective review and were matched with serous carcinoma patients for stage and residual disease. All patients received cisplatin-based chemotherapy. End points selected for analysis were surgical response, progression-free survival time, and survival time. Univariate and multivariate regression analyses were also performed.
The surgical complete response rate for patients with transitional cell carcinoma was 37%, compared with 11% for those with serous carcinoma (p < 0.001). The survival time was significantly longer for the patients with transitional cell carcinoma (median 52.3 vs 22.0 months) (p < 0.001). Multivariate analyses strengthened these findings.
Transitional cell carcinoma of the ovary is significantly more chemosensitive and associated with a better prognosis than the more common serous carcinoma.
本研究旨在比较晚期卵巢移行细胞癌患者与低分化浆液性癌患者的手术反应和生存率。
通过回顾性研究确定了62例移行细胞癌患者，并将其与浆液性癌患者的分期和残留疾病进行匹配。所有患者均接受以顺铂为基础的化疗。选择用于分析的终点指标为手术反应、无进展生存期和生存期。还进行了单因素和多因素回归分析。
移行细胞癌患者的手术完全缓解率为37%，而浆液性癌患者为11%（p<0.001）。移行细胞癌患者的生存时间明显更长（中位时间分别为52.3个月和22.0个月）（p<0.001）。多因素分析强化了这些发现。
与更常见的浆液性癌相比，卵巢移行细胞癌对化疗的敏感性明显更高，且预后更好。
